065170 — BL PharmTech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMicro CapSucker Stock

Annual income statement for BL PharmTech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	65,691	84,440	22,523	24,525	8,806
Cost of Revenue
Gross Profit	20,360	21,073	12,722	13,561	5,921
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	81,448	104,069	32,090	33,273	13,661
Operating Profit	-15,758	-19,630	-9,567	-8,748	-4,856
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-14,357	-20,570	-14,073	-13,856	-5,766
Provision for Income Taxes
Net Income After Taxes	-16,587	-20,107	-14,437	-13,810	-5,717
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-17,947	-20,211	-13,903	-149	-5,706
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-17,947	-20,211	-13,903	-149	-5,706
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-412	-444	-426	-482	-176
Dividends per Share